METHODS FOR DETERMINING THE LENGTH OF TRIPLET REPEATS

Information

  • Research Project
  • 6211613
  • ApplicationId
    6211613
  • Core Project Number
    R43NS040646
  • Full Project Number
    1R43NS040646-01
  • Serial Number
    40646
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2000 - 24 years ago
  • Project End Date
    2/28/2001 - 24 years ago
  • Program Officer Name
    SCHLOSS, JEFFERY
  • Budget Start Date
    9/1/2000 - 24 years ago
  • Budget End Date
    2/28/2001 - 24 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/18/2000 - 24 years ago
Organizations

METHODS FOR DETERMINING THE LENGTH OF TRIPLET REPEATS

We are developing innovative methods for the direct, i.e. non-amplified, detection of specific nucleic acid sequences. These methods rely on the use of our proprietary SuperTracers to increase the specific activity of the probes that are then measured with supersensitive MPD instrumentation. SuperTracers coupled to DNA probes have been developed, and multiple coincidence methods to reduce biological background are being implemented. Preliminary experiments documented that the multiple coincidence probe method permits a considerable rejection of non- specific biological background. Overall, our studies confirmed that MPD permits improved qPCR methods and innovative direct methods of nucleic acid quantitation. Further development of these innovative methods are main topics for the proposed research, especially the development of the MPD enhanced direct quantitation of triplet repeats. PROPOSED COMMERCIAL APPLICATIONS: This project will develop procedures and supporting reagents which enable reliable direct detection and quantitation of low levels of DNA. We are developing robust direct detection methods which may be performed with minimal sample preparation in the presence of high backgrounds of indigenous DNA. Such an assay system would have wide application in a number of important research, development and biomedical diagnostic activities, including: clinical diagnostics, therapy monitoring, drugs discovery and food quality testing. We will commercialize an assay system consisting of both instrumentation and supporting reagents to perform quantitative detection of DNA/RNA at very low copy number. The commercial success drivers for these products are their unique performance for the quantitative detection of DNA/RNA at levels which cannot be achieved with competing technologies.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    96345
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:96345\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOTRACES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HERNDON
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20171
  • Organization District
    UNITED STATES